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Therapeutic efficacy and the regulation of drug release can be improved by using selective targeting drug delivery systems. In this
paper, we have demonstrated avidin-immobilized magnetic nanoparticles (AMNPs) as a novel targeted drug delivery system to
deliver iminobiotinylated daunomycin (IDAU). TEM, XRD, VSM, and FTIR were employed for the physicochemical
characterization of the drug-loaded MNPs. The binding of IDAU had little effect on sizes of AMNPs (~35 nm), but the stability
and dispersibility of the nanoparticles were improved. The study also found that the loading capacity and efficiency of
nanoparticles were mainly dependent on affinity interaction between IDAU and AMNPs. The optimal loading capacity and
efficiency of MNPs for IDAU were 0.408± 0.012mg/g and 94.18± 2.64% according to the reversed-phase high-performance
liquid chromatography (RP-HPLC) data, respectively. Under the conditions of pH 6.8 and 1mmol/L of biotin, the drug-loaded
MNPs released rapidly at beginning and then maintained at a certain controllable release level. The effect of IDAU on DLKP
proliferation was tested, and the results showed that IC50 was (1.60± 0.05)× 10−3mg/mL. Our findings indicated that AMNPs
hold tremendous potential as an effective drug delivery system.
1. Introduction
Preventing the spread of malignant cells in the human body
is a matter of serious concern. Presently, surgical resection,
radiation, and chemotherapy are generally used to treat the
cancer cells, but the selection of the treatment option
depends on the location of the tumor and whether the tumor
is at an early or advanced stage. Meanwhile, new types of
anticancer drugs are being developed unceasingly [1–3],
and some drug delivery devices/systems have received con-
siderable attention, such as macromolecular carrier system
[4], microcapsule drug delivery system [5], and magnetic
drug delivery system [6–8].
The biggest challenge in drug delivery is the transporta-
tion of drug agents to the targeted site at the appropriate time
[9]. The release rate of conventional administered antitumor
drugs or injections is uncontrolled, which may lead to harm-
ful side effects and toxicity due to quick drug release. For an
excellent drug delivery system, it must be controllable and
then the therapeutic levels can extend over long periods of
time, which can eliminate the abovementioned side effects
and toxicity. In the controlled delivery, the drug delivery
may commence with first-order kinetics to an optimum
and effective drug concentration to the targeted site, followed
by zero-order kinetics, which may be one of the best ways to
release the drug. There are two controlled-release mecha-
nisms for selected drug delivery systems. One mechanism is
physical adsorption, and the drug may be automatically
released at the appropriate time. Biodegradable polymers,
for example, adsorb the drugs due to hydrogen bond and/
or dipole-charge interactions with the polymer chains. The
main disadvantage of this system is that it cannot effectively
control the rate of drug release. The other mechanism is that
the drugs are attached to a carrier through a covalent bond or
via an affinity interaction, the most common affinity tag of
this type being the avidin-biotin system [10, 11]. This drug
delivery system has an advantage that it is influenced by the
ambient factors tinily. However, the drugs are difficult to
release from the carrier in the condition of pH6.8. The imi-
nobiotin coupled with anticancer drugs shows a high affinity
to avidin (and avidin-immobilized magnetic nanoparticles
(AMNPs)) at elevated pH (9.5–10.8) but releases the drugs
easily at lower pH (~4) or under the presence of a certain
concentration of biotin at pH6.8 according to the manufac-
turer’s instructions. In this system, the drug release can be
controlled under mild conditions. Therefore, the application
of avidin-iminobiotin technology in drug delivery systems
creates an opportunity for the development of new smart
drug delivery systems because of its controllable, easy release
of the drug under the condition of pH6.8.
There is currently a great concern about magnetic field-
induced, targeted drug delivery [12–15], in spite of extensive
applications of MNPs in biomedical and diagnostic fields and
nanoreactor systems, including in vitro cell separation,
in vivo antimycotic agent, contrast agent for magnetic reso-
nance imaging, magnetic particle imaging, hyperthermia,
tumor therapy, or cardiovascular disease [16–24]. The conju-
gation of a drug to magnetic nanoparticle (MNP) entrapped
polymer or antibody is an effective method for controlled
delivery of the drug to the targeted site. Under such medica-
tion, the drug can be released at the desired location and act
locally until the therapy is completed. Therefore, the dosage
of medication can be reduced, and the harmful side effects
and toxicity of drugs kept to a minimum [25, 26]. It is worth
noting that the MNPs used for the drug delivery system
always require adequate magnetic strength, biocompatibility,
and functional active groups on the surface [27]. Nanoparti-
cles used in the drug-loaded system will generally be admin-
istered by intravenous injection and then transported in the
blood. Therefore, the dispersibility and biocompatibility in
blood and interaction between plasma proteins and MNPs
should be fully considered [28, 29].
The conjugation of a drug to MNPs functionalized
with polymer or bioactive macromolecules is a viable method
for controlled delivery of a drug to the desired site. In the
present study, an iminobiotinylated drug, iminobiotinylated
daunomycin (IDAU), was connected to avidin-immobilized
magnetic nanoparticles (AMNPs) based on the avidin-
iminobiotin binding system. The drug loading capacity and
release behavior were then determined through adsorption/
dissociation kinetics experiments, and the inhibitory effects
of IDAU on liver tumor cell DLKP growth was also evaluated.
2. Experiment
2.1. Materials.Unless stated, all chemicals were commercially
available and of analytical grade. EZ-Link® NHS-iminobiotin
and DLKP cell medium were purchased from Invitrogen
(Life Technologies, Carlsbad, CA, USA). DAU hydrochloride
standard preparation was purchased from Sigma. Fetal
bovine serum (FBS) was purchased from Hangzhou Sijiqing
Company (Hangzhou, China). Other chemicals were of
laboratory grade purity and used as obtained.
2.2. Preparation of Functionalized MNPs
2.2.1. Preparation and Glutaraldehyde Activation of PEI-
Coated MNPs.MNPs were prepared via a facile solvothermal
synthesis method, in which polyethyleneimine (PEI) was
used as the protective agent to prevent the particles from
aggregation [30]. The typical synthetic procedure was as fol-
lows. FeCl3·6H2O (0.135 g), PEI (0.5 g), and sodium acetate
(1.8 g) were added to ethylene glycol (20.0mL) to form col-
loid mixture under vigorous stirring at room temperature
for 45min. Then, 18.0mL of the mixture was sealed in
Teflon-lined stainless steel autoclave of 20mL capacity.
Finally, the autoclave was heated and maintained at 200°C
for 12 h and allowed to cool down to room temperature nat-
urally. The back products were washed twice with absolute
ethanol and twice with Milli-Q water. MNPs were then dis-
persed in Milli-Q water and stored in sealed cell (50mL) at
room temperature.
To activate PEI-coated MNPs with glutaraldehyde, the
nanoparticles were dispersed in 20mL PBS buffer (0.1mol/L,
pH8.0) containing 2% glutaraldehyde. The suspension
was mechanically stirred at room temperature in the dark
for 4 h. The glutaraldehyde-activated MNPs were separated
from unconjugated glutaraldehyde by magnetically driven
separation at room temperature for 5min and then washed
three times with PBS buffer (0.1mol/L, pH8.0). The final
glutaraldehyde-activated MNPs were dispersed in 20mL
PBS buffer (0.1mol/L, pH8.0) and kept in the dark at 4°C
until use.
2.2.2. Immobilization of Avidin onto MNPs. To immobilize
avidin, 15mg of glutaraldehyde activated MNPs was dis-
persed in 20mL PBS buffer (0.1mol/L, pH8.0) and sonicated
for 5 s at 20W by a Ti probe (Branson 450 sonifier). 5mL of
avidin (100μg/mL) was introduced to the PBS buffer solu-
tion, and the suspension was mechanically stirred at 4°C in
the dark for 4 h. AMNPs were separated from unconjugated
avidin by magnetically driven separation at 4°C for 5min
and then washed three times with PBS buffer (0.1mol/L,
pH8.0). The final AMNPswere dispersed in 20mLPBS buffer
(0.1mol/L, pH8.0) and kept in the dark at 4°C until use.
2.3. Conjugation of Drug to AMNPs
2.3.1. Preparation of IDAU. IDAU was prepared by reaction
between 1.5mg DAU and 1.0mg NHS-iminobiotin at 4°C
for 24 h in 20mL of PBS buffer (0.1mol/L, pH10.8), and then
the buffer was adjusted to pH8.0 with 1mol/L phosphoric
acid. The product need not be separated from the excessive
DAU and kept in the dark at 4°C until use.
2.3.2. Conjugation of IDAU to MNPs. AMNPs were dis-
persed in 20mL of PBS buffer (0.1mol/L, pH8.0) containing
0.1mg/mL of IDAU, followed by incubation for 4 h at 4°C
with gentle stirring. The DAU-loaded MNPs were separated
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from the solution with the aid of a magnet and then washed
three times with PBS buffer (0.1mol/L, pH8.0). The final
IDAU-loaded MNPs (IDAU-MNPs) were dispersed in
20mL PBS buffer (0.1mol/L, pH7.0) and kept in the dark
at 4°C until use. A schematic of the different steps in the
preparation of iminobiotinylated daunomycin-loaded Fe3O4
nanoparticles (IDAU-MNPs) is summarized in Figure 1.
2.4. Physicochemical Characterization of MNPs
2.4.1. Particle Shape Analysis and Size Analysis. The size and
morphology of AMNPs and DAU-immobilized MNPs were
examined under a transmission electron microscope (TEM)
operated at 100KV (model JEM 2010, JeM Inc., Japan).
The nanoparticles were first diluted in deionized water to
an appropriate concentration (7.5μg/mL) and then ultraso-
nicated for 10 s. A copper grid (200 mesh and cover with for-
mvar/carbon) was coated with the thin layer of diluted
particle suspension and allowed to stand for 2min. The
excess liquid was drained off by filter paper and the samples
were then examined by TEM.
2.4.2. X-Ray Diffraction (XRD). XRD experiments of the
crystalline phase of a powder sample of MNPs, AMNPs, and
IDAU-MNPs were performed using an X-ray diffractometer
(Rigaku D/max-γ, Japan) and Cu-Kα (λ=0.154056nm) radi-
ation. The parameters of the measurements were: 40 kV and
20mA, angular variation ranging from 20 to 80° in steps of
10.0° for each 1min (geometry θ–2θ).
2.4.3. Vibrating-Sample Magnetometry (VSM). MNPs,
AMNPs, and IDAU-MNPs were checked for magnetic sus-
ceptibility using vibrating-sample magnetometer (PARC,
155, USA) which provided magnetization (emu g−1) of mag-
netic particles in response to an external magnetic field (Oe).
2.4.4. Fourier-Transform Infrared Spectroscopy (FTIR). Avi-
din and DAU anchoring onto the surface of MNPs were
monitored by FTIR. Data were collected on a Nicolet
Avatar-330 Spectrometer (Thermo Nicolet, USA) with
4 cm−1 resolution using the KBr pellet technique.
2.5. Drug Loading Determination (Indirect Estimation). The
degree of IDAU incorporation into AMNPs was analyzed
by RP-HPLC and monitored using a UV-VIS detector.
IDAU-MNPs were separated from unconjugated DAU and
IDAU by magnetically driven separation at 4°C for 5min
and then rinsed with PBS buffer (0.1mol/L, pH8.0) until
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acetate, FeCl3.6H2O







































Figure 1: Schematic of the different steps in the preparation of iminobiotinylated daunomycin-loaded Fe3O4 nanoparticles.
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no DAU was detected in washings. The IDAU loading capac-
ity (LC, mg/g) was determined as
LC mg/g = 100 × Cd
Cn
= 100 × C0 − C1
Cn
, 1
where Cd, Cn, C0, and C1 are the concentrations of IDAU
incorporated in nanoparticles (mg/mL), MNPs offered for
DAU incorporation (g/mL), initial additions of IDAU
(mg/mL), and IDAU remained in PBS buffer after the
DAU-loaded MNPs were separated from the solution
(mg/mL), respectively.
2.6. In Vitro Evaluation of the Anticancer Drug
2.6.1. Kinetics of Drug Release. Two methods for drug release
were investigated in our experiments. On the one hand,
appropriate amounts of IDAU-MNPs samples were dis-
persed in 20mL of incubation medium (PBS buffer contain-
ing 1mM of biotin, pH6.8) and maintained under constant
mild agitation in a water bath (37°C). On the other hand,
the same amounts of drug-loaded MNPs samples were dis-
persed in 20mL of 0.1mol/L ammonium acetate buffer at
pH4.0 (the buffer containing 0.5mol/L NaCl and 1.0mmol/L
EDTA) and maintained under constant mild agitation in a
water bath (37°C). The final concentration of IDAU was cho-
sen to ensure sink conditions for the in vitro study. Aliquots
(15μL) were taken in predetermined time intervals from 2 to
540min. Each aliquot was analyzed with RP-HPLC for IDAU
content as described above.
2.6.2. In Vitro Cytotoxicity. A proliferation method was used
to measure the cytotoxicity of IDAU-MNP samples towards
the DLKP cell line [30–33], with slight modifications. Cyto-
toxicity of drugs was measured as previously described.
Briefly, cells were seeded at 1× 103 cells/well in a 96-well plate
and left to attach overnight in a 5% CO2 incubator at 37
°C.
The appropriate concentrations of IDAU-MNPs were pre-
pared freshly at twice their final concentration and added to
the plate on the following day. The assay was terminated after
further 7-day incubation. The effect of treatment was exam-
ined by comparing the growth of cells in the treated rows to
the growth of cells in the control rows and expressed as per-
centage. All assays were performed at least in triplicate.
3. Results and Discussion
3.1. Physicochemical Characterization of MNPs
3.1.1. Transmission Electron Microscope and X-Ray Diffraction.
Typical TEM micrographs for AMNPs and IDAU-MNPs
were shown in Figures 2(a) and 2(b), respectively, which
indicated that the diameter of these particles was approx-
imately 35 nm. The shape of MNPs was spherical and its
particles were well-distributed. After the IDAU was con-
nected to AMNPs, no significant difference in sizes of
AMNPs and IDAU-MNPs were observed, but the IDAU-
MNPs had more uniform size distribution. Because of these
features of MNPs described above, MNPs had good sta-
bility, better dispersibility, huge surface area, and greater
loadspace. It was also observed in our study that the dis-
persity and stability of MNP-loaded IDAU increased
compared to AMNPs, indicating that the hydrophilic
groups on the MNP surface increased and the biocom-
patibility of MNPs enhanced when IDAU was loaded onto
the nanoparticles.
Crystallinity and crystal size are important properties to
be considered for the present study as they affect the mag-
netic susceptibility. X-ray diffraction is a useful technique
for characterizing the crystalline samples. XRD patterns
(Figure 3(a)) of MNPs, AMNPs, and IDAU-MNPs were used
for determining the crystallographic identity and phase
purity and for calculating the average crystallite diameter
based on the full width at half maximum (FWHM) in the
XRD profile. There were 6 peaks at 30.14, 35.47, 43.14,
53.45, 57.08, and 62.63 (2θ) in the XRD profile, which was
characteristic of Fe3O4. It was confirmed by ICDD database
(reference code 01076-0955) and showed 100% purity. The
average crystallite size of MNPs was calculated by the X-ray
line broadening method by the use of Debye–Scherrer’s
equation taking FWHM of peak at 35.47 (2θ) as this peak
showed least interferences, giving the average particle size





Figure 2: TEM images of AMNPs (a) and IDAU-MNPs (b).
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and IDAU-MNPs, respectively. These sizes are in agree-
ment with the sizes measured by TEM.
It is very important that the prepared MNPs possesses
sufficient magnetic and superparamagnetism property for
practical application. Figure 3(b) displayed the VSM mag-
netization curves of AMNPs and IDAU-MNPs at room tem-
perature; the results indicated the saturation magnetization
of AMNPs and IDAU-MNPs were 64.92 and 59.63 emu g−1,
respectively. All of the magnetic nanoparticles showed
quasi-superparamagnetic behavior and had little remanence
and coercivity. Drug loading into MNPs in significant
amounts resulted in the slight decrease in magnetic strength
of the composite because of the weight contribution from the
nonmagnetic portion. The saturation magnetization of
IDAU-MNPs was sufficient for the magnetically driven
transport of drugs with a conventional magnet.
3.1.2. Fourier-Transform Infrared Spectroscopy (FTIR). FTIR
spectroscopy is an appropriate technique to confirm drug
insertion into the nanoparticles. In the FTIR spectrum of
AMNPs (Figure 4(a)), three strong bands were observed at
568.0, 1637.1, and 1655.4 cm−1. The first was due to the
Fe-O stretching mode of the Fe3O4 MNPs, and the second
and thirdwere associatedwith theα-helical andβ-folded types
of secondary structure of avidin, respectively [34, 35]. The
presence of two bands at 1637.1 and 1655.4 cm−1 confirmed
that avidin was immobilized successfully on Fe3O4MNPs.
In the FTIR spectrum of IDAU (Figure 4(b)), the charac-
teristic C=O (hydrogen-bonded quinone carbonyl group),
C=C, and C-OH stretching modes of IDAU were observed
at 1618.0, 1578.1, and 1115.9 cm−1, respectively [36], and
there was a large difference in intensity between the two
strong bands at 1618.0 and 1578.1 cm−1. However, in the
FTIR spectrum of DAU, two strong bands of similar
intensity were found at 1617.0 and 1580.0 cm−1 [37]. The
intensity changes in the infrared spectra showed that the
molecular structure of DAU was changed after it was 2-













































Figure 3: XRD diffractogram of MNPs (black), AMNPs (red), and IDAU-MNPs (blue) (a) and the magnetic hysteresis loops for AMNPs












































































Figure 4: FTIR spectra of avidin-immobilized magnetic nanoparticles
(a), daunomycin (b), and iminobiotinylated daunomycin-loaded
magnetic nanoparticles (c).
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N-H stretching modes of IDAU were also observed at 1210.0
and 1289.7 cm−1, respectively [38], but they were not found
in DAU, which indicated IDAU was successfully prepared
by reaction between DAU and NHS-iminobiotin.
In the FTIR spectrum of IDAU-MNPs (Figure 4(c)), the
characteristic absorption of Fe-O bond of drug-loadedMNPs
was discovered at 553.8 cm−1, which shifted from 568.0 to
553.8 cm−1 (Figure 4(a)). The characteristic C-OH stretching
mode of drug-loaded MNPs was observed at 1117.7 cm−1.
There was strong evidence for the presence of drug mole-
cules in MNPs. However, the characteristic bands (such as
at 1618.0 and 1578.1 cm−1) of IDAU could not be found
after it was connected to MNPs, with the exception of the
band assigned to C-OH, which shifted from 1115.9 to
1117.7 cm−1 (Figure 4(b)). The absence of the two character-
istic bands confirmed a strong interaction between IDAU
and AMNPs.
3.2. Drug Loading Determination
3.2.1. Determination of DAU and IDAU. RP-HPLC
adopted to determine DAU has the advantages of high
sensitivity and good reproducibility. The chromatogram
of RP-HPLC determining DAU was shown in Figure 5(a).
According to the result, the retention time of DAU was at
6.00min, and the intralaboratory reproducibility was very
good, with 90% of the replicates analyzed in the same labora-
tory differing by ≤2.8%. The regression equation for deter-
mining DAU was established through several experiments
(y=31139161.20x − 54373.54, where y was the peak area
and x was the concentration of DAU, R2 = 0 9995). IDAU
was generated by reaction of DAU with NHS-iminobiotin
in alkaline condition. The best rate of DAU acylation
determined by the above formula was 78.90± 2.13%. After
the reaction between excessive DAU and NHS-iminobio-
tin, RP-HPLC was used to analyze IDAU. The chromato-
gram of the DAU and IDAU mixture was shown in
Figure 5(b). The results showed that the separation effect
of liquid chromatography about these two substances was
very good, and the retention time of DAU excessed was
at 6.05min, while the retention time of IDAU was at
2.00min. Here, we created a standard curve and used linear
regression analysis (called a trendline in excel) to determine
the concentration of IDAU (y =31139161.20x− 54373.54,
where y was the peak area and x was the concentration of
IDAU, R2 = 0 9991).
3.2.2. Adsorption Dynamics of IDAU on AMNPs. The drug
loading efficiency of MNPs and their loading capacity are
two important indicators for the drug delivery system. For
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Figure 5: HPLC analysis of the mixtures containing only daunomycin (a), iminobiotinylated daunomycin, and daunomycin (b).
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loading capacity were studied using indirect RP-HPLC anal-
ysis. The results were presented in Figure 6. When the initial
concentration of IDAU was less than 7mg/mL, the loading
efficiency of more than 90% was observed. However, upon
increasing the initial drug concentration, the loading effi-
ciency decreased rapidly, but the drug adsorption capacity
was unchanged. This strongly suggested that the drug
adsorption behaviors were mainly dependent on affinity
interaction between IDAU and AMNPs, and the nonspe-
cific adsorption of the drug was extremely low. The same
phenomenon could also be observed in the other molecu-
lar adsorption processes using the avidin-biotin binding
system [39–41]. The increase of the initial concentration
of IDAU needs more iminobiotin binding sites of AMNPs.
When the iminobiotin binding sites of AMNPs were not
sufficiently high (saturation) with increasing IDAU con-
centration, the amount of specific adsorption capability for
IDAU was unchanged. Therefore, the optimum initial con-
centration of IDAU was 7mg/mL, and the loading capacity
and loading efficiency of MNPs were 0.408± 0.012mg/g
and 94.18± 2.64%, respectively. Compared with the drug
loaded into MNPs through physical encapsulation or adsorp-
tion, the drug connected to AMNPs based on the avidin-
iminobiotin system would not be easily released during
transportation of the drug due to the effects of environmental
parameters such as temperature, pH, ionic strength, and
sodium nitrate. The drugs could be delivered to the targeted
site at the appropriate time successfully. The controllable
drug delivery system could maximize its bioefficacy, reduce
the side effects, and facilitate clinical applicability [42].
3.3. Performance Evaluation of Drug-
Nanoparticle Formulations
3.3.1. In Vitro Drug Release. The in vitro drug release from
IDAU-MNPs was monitored as a function of time in PBS
buffer at pH6.8 or in ammonium acetate buffer at pH4.0 as
shown in Figures 7(a) and 7(b), respectively. For method 1,
IDAU could be completely released from MNPs for 30min
at pH4.0, but the drug did not readily dissociate at pH6.8.
The reason was that the drug release behavior from nanopar-
ticles was mainly dependent on the interaction between
IDAU and AMNPs at different pH values [43–45]. Practical
applications of method 1 in the clinical laboratory were lim-
ited because of the rapid and transient release of the drug and
its strict dissociation conditions. For method 2, IDAU was
released by adding a certain concentration of biotin at
pH6.8, because under that specific condition, the strength
of affinity interaction between biotin and AMNPs was more
than that of iminobiotin and AMNPs, and IDAU was
replaced by biotin. Fortunately, the conditions were relatively
mild. The amount of IDAU released to the outer medium was
measured using RP-HPLC, and the drug release data were
presented in Figure 7(c). A low concentration of biotin
(1mmol/L) was used in our research. The results showed that
the initial stage was characterized by a fast release of a limited
quantity of IDAU, and the second stage was described by a
slow, steady, and controlled release of the drug. The maxi-
mum concentration of IDAU released to the outer medium
was strongly correlated with the concentration of IDAU
loading on MNPs, but the maximum concentration of IDAU
loading on MNPs did not release the maximum concentra-
tion of IDAU at the same concentration of biotin. The release
profiles exhibited strong dependence on the concentration of
IDAU connected to MNPs. When the concentration was
0.015mg/mL, 38.9% of the loaded drug could be released
within 150min, and the concentration of the drug released
was 5.84μg/mL. When the concentration of IDAU con-
nected to MNPs was 0.055mg/mL, only 10.5% of the loaded
drug could be released within the same time, and the concen-
tration of the drug released was 5.78μg/mL. However, when
the concentration of the drug connected to MNPs was
0.035mg/mL, the concentration of the drug released could
reach 6.49μg/mL. According to these results, it could be con-
cluded that the optimum concentration of IDAU connected
to MNPs was 0.035mg/mL. The different concentrations of
the drug released might be attributed to the interaction
between biotin and drug-loaded MNPs, and the interaction
was a complex, dynamic process. The first process was the
dissociation of IDAU from AMNPs at pH6.8. At the same
time, a high concentration of biotin and strong affinity inter-
action between biotin and avidin at pH6.8 promoted the
interaction between biotin and AMNPs, and the loaded
IDAU would be rapidly released. When the dissociation reac-
tions between IDAU and AMNPs reached equilibrium, a
slow, steady, and controlled release of the drug would be
obtained. However, the majority of drugs would overcome
some resistance to diffuse across avidin and PEI to the surface
of MNPs and finally into aqueous medium. A high concen-
tration of IDAU connected to MNPs might need more pro-
teins and polymers and create conversely more resistance to
hold back the effective drug release. Therefore, a low concen-
tration of released IDAU present in the aqueous medium
would be obtained.
3.3.2. Toxicity in Cell Culture. The potential of AMNPs to
be used as a carrier for IDAU was evaluated in vitro by
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Figure 6: Dependence of the loading capacity (□) and loading
efficiency (○) on initial concentration of iminobiotinylated
daunomycin used during the preparation. Each result is the
average calculated in 95% confidence interval of five parallel studies.
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DAU(Sample 1), 0.04mg/mL; IDAU (sample 2), 0.06mg/mL;
IDAU-MNPs (the concentration of IDAU on the surface
was 0.06mg/mL, sample 3); and unloaded MNPs (AMNPs,
sample 4), 0.15mg/mL. The in vitro models chosen for
investigating the potential of these materials were the
DLKP cell line, and 50% inhibitory concentrations (IC50)
of the four samples were determined. As depicted in
Figure 8, the results indicated that the IC50 of IDAU
was (1.60± 0.05)× 10−3mg/mL, and it retained significant
activity against DLKP cells (P < 0 05), although its antitu-
mor activity was lower than that of free DAU. The IC50
of IDAU-MNPs was 0.02± 0.007mg/mL and was much
lower than that of free DAU or IDAU, but the presence
of low activity against DLKP cells confirmed that a small
quantity of IDAU on the surface of MNPs stretched in
aqueous medium and interacted with tumor cells. Another
reason that IDAU-MNPs had anticancer activity in vitro
was a pumping mechanism that enabled diffusion of the
drug out of avidin on the surface of nanoparticles [46–48].
The above experimental data clearly demonstrated that
IDAU could not only be adsorbed, transported, and released
controllably on the surface of MNPs but also exhibited high
inhibitory activity against DLKP cells. However, since the
delivery of the drug from MNPs carriers in vivo was a com-
plex process, the effectiveness of the present method needs
to be further verified. Furthermore, the in vivo tumor inhibi-
tion experiments in the external magnetic field are in prog-
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Figure 7: Two methods for releasing of iminobiotinylated daunomycin from nanoparticles and drug release behavior as a function of loaded
iminobiotinylated daunomycin concentration (0.015mg/mL (blue triangle), 0.035mg/mL (red circle), and 0.055mg/mL (black square)). Each
result is the average calculated in 95% confidence interval of five parallel studies.
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to achieve the magnetic drug targeting and improve the ther-
apeutic efficacy.
4. Conclusion
We described here a novel experimental approach to the
design and preparation of IDAU-MNPs through the affinity
interaction between IDAU and AMNPs. DAU was first 2-
iminobiotinylated, which was then attached to AMNPs using
the avidin-iminobiotin system. The results obtained using
RP-HPLC studies indicated that the optimal acylation rate
of IDAU was 78.90± 2.13%. The results obtained using FTIR
studies strongly suggested that IDAU could be firmly affixed
to AMNPs using the avidin-iminobiotin system. The study
also found that the loading capacity and efficiency of nano-
particles were mainly dependent on affinity interaction
between IDAU and AMNPs, which was impacted obviously
by the initial concentration of IDAU. Under the conditions
of pH6.8 and 1mmol/L of biotin, the drug release was
characterized by an initial rapid drug release followed by
a slow, steady and controlled release of the drug. The effect
of IDAU on DLKP proliferation was tested, the results
showed that IC50 was (1.60± 0.05)× 10−3mg/mL. It could
come to a conclusion that the drug had good inhibitory
effect on tumor cell growth.
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